Premium
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate‐to‐severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm
Author(s) -
Belinchón I.,
Ramos J.M.,
Carretero G.,
Ferrándiz C.,
Rivera R.,
Daudén E.,
De la CuevaDobao P.,
GómezGarcía F.J.,
HerreraCeballos E.,
SánchezCarazo J.L.,
LópezEstebaranz J.L.,
Alsina M.,
Ferrán M.,
Torrado R.,
Carrascosa J.M.,
LlamasVelasco M.,
Ortiz P.L.,
GarcíaDoval I.,
Descalzo M.A.
Publication year - 2017
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.14314
Subject(s) - medicine , discontinuation , ustekinumab , psoriasis , adverse effect , incidence (geometry) , observational study , cohort , cohort study , infliximab , dermatology , disease , physics , optics
Background Little is known about the adverse events ( AE s) that lead to suspension of systemic treatments for psoriasis in clinical practice. Objective The study aimed to investigate AE s associated with discontinuation of systemic therapy in patients with psoriasis in a clinical setting (Biobadaderm). Materials and methods Multicentre, prospective, cohort study of patients with moderate‐to‐severe plaque psoriasis receiving systemic therapies from January 2008 to November 2015, in 12 hospitals in Spain. The incidence rate ( IR ) was used to compare biologics and classic systemic therapies. Results A total of 4218 courses of treatment were given to 1938 patients. A total of 447 (11%) treatments were discontinued due to AE s. The IR of AE associated with discontinuation of systemic therapies was 13 events/100 patient‐years ( PY ) (95% CI : 12.14–13.93), 9.34 events/100 PY (95% CI : 8.44–10.33) for biologics and 19.67 (95% CI : 17.9–21.6) events/100 PY for classics ( P < 0.001). Of 810 discontinuation‐related AE s, 117 (14%) were serious. The highest IR s were for cyclosporine [49.18/100 PY (95% CI : 41.91–57.72)] and infliximab [26.52/100 PY (95% CI : 20.98–33.51). Ustekinumab presented the lowest IR (2.6/100 PY (95% CI : 1.83–3.69). Limitations Observational study with potential selection bias. Conclusion Biologic therapies are associated with a lower rate of discontinuation‐related AE s than are classic therapies in real clinical practice. Ustekinumab showed the lowest incidence.